Breast cancer is the most frequently diagnosed malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. To assist women who are at increased risk of developing breast cancer and their physicians in the application of individualized strategies to reduce breast cancer risk, NCCN has developed these guidelines for breast cancer risk reduction.

  • 1.

    SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:929.

  • 2.

    SiegelRLMillerKDJemalA. Cancer statistics, 2015. CA Cancer J Clin2015;65:529.

  • 3.

    FreedmanANYuBGailMH. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol2011;29:23272333.

    • Search Google Scholar
    • Export Citation
  • 4.

    GossPEIngleJNAles-MartinezJE. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med2011;364:23812391.

  • 5.

    CuzickJSestakIForbesJF. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet2014;383:10411048.

    • Search Google Scholar
    • Export Citation
  • 6.

    MurffHJByrneDSyngalS. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med2004;27:239245.

  • 7.

    MurffHJSpigelDRSyngalS. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA2004;292:14801489.

    • Search Google Scholar
    • Export Citation
  • 8.

    WoosterRBignellGLancasterJ. Identification of the breast cancer susceptibility gene BRCA2. Nature1995;378:789792.

  • 9.

    MikiYSwensenJShattuck-EidensD. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science1994;266:6671.

    • Search Google Scholar
    • Export Citation
  • 10.

    MalkinDLiFPStrongLC. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science1990;250:12331238.

    • Search Google Scholar
    • Export Citation
  • 11.

    van LierMGWagnerAMathus-VliegenEM. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol2010;105:12581264; author reply 1265.

    • Search Google Scholar
    • Export Citation
  • 12.

    TanMHMesterJLNgeowJ. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res2012;18:400407.

  • 13.

    BubienVBonnetFBrousteV. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet2013;50:255263.

  • 14.

    BerxGStaesKvan HengelJ. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics1995;26:281289.

    • Search Google Scholar
    • Export Citation
  • 15.

    ColditzGAWillettWCHunterDJ. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA1993;270:338343.

    • Search Google Scholar
    • Export Citation
  • 16.

    SlatteryMLKerberRA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA1993;270:15631568.

    • Search Google Scholar
    • Export Citation
  • 17.

    ColditzGAKaphingstKAHankinsonSERosnerB. Family history and risk of breast cancer: nurses' health study. Breast Cancer Res Treat2012;133:10971104.

    • Search Google Scholar
    • Export Citation
  • 18.

    LynchHTWatsonPConwayTALynchJF. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat1990;15:6371.

  • 19.

    PharoahPDDayNEDuffyS. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer1997;71:800809.

    • Search Google Scholar
    • Export Citation
  • 20.

    BerlinerJLFayAM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns2007;16:241260.

    • Search Google Scholar
    • Export Citation
  • 21.

    FoulkesWD. Inherited susceptibility to common cancers. N Engl J Med2008;359:21432153.

  • 22.

    PharoahPDAntoniouABobrowM. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet2002;31:3336.

  • 23.

    TrepanierAAhrensMMcKinnonW. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns2004;13:83114.

    • Search Google Scholar
    • Export Citation
  • 24.

    ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643651.

    • Search Google Scholar
    • Export Citation
  • 25.

    TyrerJDuffySWCuzickJ. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med2004;23:11111130.

  • 26.

    AmirEEvansDGShentonA. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet2003;40:807814.

    • Search Google Scholar
    • Export Citation
  • 27.

    EvansDGHowellA. Breast cancer risk-assessment models. Breast Cancer Res2007;9:213.

  • 28.

    SaslowDBoetesCBurkeW. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57:7589.

    • Search Google Scholar
    • Export Citation
  • 29.

    ClausEBRischNThompsonWD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat1993;28:115120.

    • Search Google Scholar
    • Export Citation
  • 30.

    ParmigianiGBerryDAguilarO. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet1998;62:145158.

    • Search Google Scholar
    • Export Citation
  • 31.

    AntoniouACCunninghamAPPetoJ. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer2008;98:14571466.

    • Search Google Scholar
    • Export Citation
  • 32.

    RoaBBBoydAAVolcikKRichardsCS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet1996;14:185187.

    • Search Google Scholar
    • Export Citation
  • 33.

    LiCIMaloneKEDalingJR. Timing of menarche and first full-term birth in relation to breast cancer risk. Am J Epidemiol2008;167:230239.

    • Search Google Scholar
    • Export Citation
  • 34.

    YangXRChang-ClaudeJGoodeEL. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst2011;103:250263.

    • Search Google Scholar
    • Export Citation
  • 35.

    IslamTMatsuoKItoH. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol2012;23:24352441.

    • Search Google Scholar
    • Export Citation
  • 36.

    LiCIBeaberEFTangMT. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat2013;137:579587.

    • Search Google Scholar
    • Export Citation
  • 37.

    ChlebowskiRTHendrixSLLangerRD. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA2003;289:32433253.

    • Search Google Scholar
    • Export Citation
  • 38.

    EmausMJvan GilsCHBakkerMF. Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer2014;135:28872899.

    • Search Google Scholar
    • Export Citation
  • 39.

    KeyTJApplebyPNReevesGK. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst2003;95:12181226.

    • Search Google Scholar
    • Export Citation
  • 40.

    SuzukiRIwasakiMInoueM. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status--the Japan public health center-based prospective study. Int J Cancer2011;129:12141224.

    • Search Google Scholar
    • Export Citation
  • 41.

    SuzukiRRylander-RudqvistTYeW. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. Int J Cancer2006;119:16831689.

    • Search Google Scholar
    • Export Citation
  • 42.

    FeigelsonHSPatelAVTerasLR. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer2006;107:1221.

    • Search Google Scholar
    • Export Citation
  • 43.

    VrielingABuckKKaaksRChang-ClaudeJ. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat2010;123:641649.

    • Search Google Scholar
    • Export Citation
  • 44.

    HanDNieJBonnerMR. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer2006;119:29312937.

    • Search Google Scholar
    • Export Citation
  • 45.

    KawaiMMinamiYKuriyamaS. Adiposity, adult weight change and breast cancer risk in postmenopausal Japanese women: the Miyagi Cohort Study. Br J Cancer2010;103:14431447.

    • Search Google Scholar
    • Export Citation
  • 46.

    EliassenAHColditzGARosnerB. Adult weight change and risk of postmenopausal breast cancer. JAMA2006;296:193201.

  • 47.

    SingletaryKWGapsturSM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA2001;286:21432151.

    • Search Google Scholar
    • Export Citation
  • 48.

    HamajimaNHiroseKTajimaK. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer2002;87:12341245.

    • Search Google Scholar
    • Export Citation
  • 49.

    ChenWYRosnerBHankinsonSE. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA2011;306:18841890.

    • Search Google Scholar
    • Export Citation
  • 50.

    RosenbergLBoggsDABetheaTN. A prospective study of smoking and breast cancer risk among African-American women. Cancer Causes Control2013;24:22072215.

    • Search Google Scholar
    • Export Citation
  • 51.

    GaudetMMGapsturSMSunJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst2013;105:515525.

    • Search Google Scholar
    • Export Citation
  • 52.

    MarshallLMHunterDJConnollyJL. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev1997;6:297301.

    • Search Google Scholar
    • Export Citation
  • 53.

    HartmannLCRadiskyDCFrostMH. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila)2014;7:211217.

    • Search Google Scholar
    • Export Citation
  • 54.

    CoopeySBMazzolaEBuckleyJM. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat2012;136:627633.

    • Search Google Scholar
    • Export Citation
  • 55.

    BhatiaSYasuiYRobisonLL. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol2003;21:43864394.

    • Search Google Scholar
    • Export Citation
  • 56.

    TravisLBHillDDoresGM. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst2005;97:14281437.

    • Search Google Scholar
    • Export Citation
  • 57.

    HancockSLTuckerMAHoppeRT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst1993;85:2531.

  • 58.

    HudsonMMPoquetteCALeeJ. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol1998;16:35923600.

  • 59.

    van LeeuwenFEKlokmanWJStovallM. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst2003;95:971980.

    • Search Google Scholar
    • Export Citation
  • 60.

    YahalomJPetrekJABiddingerPW. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol1992;10:16741681.

    • Search Google Scholar
    • Export Citation
  • 61.

    GreendaleGAReboussinBASloneS. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst2003;95:3037.

  • 62.

    BoydNFGuoHMartinLJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med2007;356:227236.

  • 63.

    BoydNFRommensJMVogtK. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol2005;6:798808.

  • 64.

    ChiuSYDuffySYenAM. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev2010;19:12191228.

    • Search Google Scholar
    • Export Citation
  • 65.

    VachonCMSellersTAScottCG. Longitudinal breast density and risk of breast cancer [abstract]. Cancer Research2011;70:Abstract 4828.

  • 66.

    WongCSLimGHGaoF. Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer2011;104:871874.

    • Search Google Scholar
    • Export Citation
  • 67.

    CostantinoJPGailMHPeeD. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst1999;91:15411548.

    • Search Google Scholar
    • Export Citation
  • 68.

    GailMHBrintonLAByarDP. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst1989;81:18791886.

    • Search Google Scholar
    • Export Citation
  • 69.

    SpiegelmanDColditzGAHunterDHertzmarkE. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst1994;86:600607.

    • Search Google Scholar
    • Export Citation
  • 70.

    GailMHCostantinoJP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst2001;93:334335.

    • Search Google Scholar
    • Export Citation
  • 71.

    RockhillBSpiegelmanDByrneC. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst2001;93:358366.

    • Search Google Scholar
    • Export Citation
  • 72.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 73.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005;97:16521662.

    • Search Google Scholar
    • Export Citation
  • 74.

    VogelVGCostantinoJPWickerhamDL. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:27272741.

    • Search Google Scholar
    • Export Citation
  • 75.

    VogelVGCostantinoJPWickerhamDL. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila)2010;3:696706.

    • Search Google Scholar
    • Export Citation
  • 76.

    GailMHCostantinoJPPeeD. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst2007;99:17821792.

    • Search Google Scholar
    • Export Citation
  • 77.

    MatsunoRKCostantinoJPZieglerRG. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst2011;103:951961.

    • Search Google Scholar
    • Export Citation
  • 78.

    PankratzVSHartmannLCDegnimAC. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol2008;26:53745379.

    • Search Google Scholar
    • Export Citation
  • 79.

    RosenPPKosloffCLiebermanPH. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol1978;2:225251.

    • Search Google Scholar
    • Export Citation
  • 80.

    HaagensenCBodianCHaagensenDJr.Breast Carcinoma: Risk and Detection. Philadelphia, PA: W.B. Saunders; 1981.

  • 81.

    BougheyJCHartmannLCAndersonSS. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol2010;28:35913596.

    • Search Google Scholar
    • Export Citation
  • 82.

    van den BrandtPASpiegelmanDYaunSS. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol2000;152:514527.

    • Search Google Scholar
    • Export Citation
  • 83.

    MahoneyMCBeversTLinosEWillettWC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin2008;58:347371.

    • Search Google Scholar
    • Export Citation
  • 84.

    ZhangSMLeeIMMansonJE. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol2007;165:667676.

  • 85.

    TerryMBZhangFFKabatG. Lifetime alcohol intake and breast cancer risk. Ann Epidemiol2006;16:230240.

  • 86.

    Smith-WarnerSASpiegelmanDYaunSS. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA1998;279:535540.

  • 87.

    AntoniouACPharoahPDEastonDFEvansDG. BRCA1 and BRCA2 cancer risks. J Clin Oncol2006;24:3312-3313; author reply 3313–3314.

  • 88.

    FordDEastonDFStrattonM. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet1998;62:676689.

    • Search Google Scholar
    • Export Citation
  • 89.

    StruewingJPHartgePWacholderS. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med1997;336:14011408.

    • Search Google Scholar
    • Export Citation
  • 90.

    HartmannLCSchaidDJWoodsJE. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med1999;340:7784.

    • Search Google Scholar
    • Export Citation
  • 91.

    HartmannLCSellersTASchaidDJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst2001;93:16331637.

    • Search Google Scholar
    • Export Citation
  • 92.

    HammRMLawlerFScheidD. Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med1999;340:18371838; author reply 1839.

    • Search Google Scholar
    • Export Citation
  • 93.

    Meijers-HeijboerHvan GeelBvan PuttenWL. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2001;345:159164.

    • Search Google Scholar
    • Export Citation
  • 94.

    RebbeckTRFriebelTLynchHT. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2004;22:10551062.

    • Search Google Scholar
    • Export Citation
  • 95.

    De FeliceFMarchettiCMusellaA. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis[published online ahead of print March 26 2015]. Ann Surg Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 96.

    BougheyJCKhakpourNMeric-BernstamF. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer2006;107:14401447.

    • Search Google Scholar
    • Export Citation
  • 97.

    MillerCLSpechtMCSkolnyMN. Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery. Breast Cancer Res Treat2012;135:781789.

    • Search Google Scholar
    • Export Citation
  • 98.

    Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer2000;83:13011308.

    • Search Google Scholar
    • Export Citation
  • 99.

    AntoniouAPharoahPDPNarodS. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet2003;72:11171130.

    • Search Google Scholar
    • Export Citation
  • 100.

    KingMCMarksJHMandellJB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science2003;302:643646.

  • 101.

    SatagopanJMBoydJKauffND. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res2002;8:37763781.

    • Search Google Scholar
    • Export Citation
  • 102.

    RebbeckTRLynchHTNeuhausenSL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med2002;346:16161622.

  • 103.

    RebbeckTRKauffNDDomchekSM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009;101:8087.

    • Search Google Scholar
    • Export Citation
  • 104.

    FinchABeinerMLubinskiJ. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA2006;296:185192.

    • Search Google Scholar
    • Export Citation
  • 105.

    KauffNDSatagopanJMRobsonME. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2002;346:16091615.

    • Search Google Scholar
    • Export Citation
  • 106.

    KemelYKauffNDRobsonME. Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. J Clin Oncol2005;23(Suppl):Abstract 1013.

    • Search Google Scholar
    • Export Citation
  • 107.

    RebbeckTRLevinAMEisenA. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999;91:14751479.

    • Search Google Scholar
    • Export Citation
  • 108.

    EisenALubinskiJKlijnJ. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol2005;23:74917496.

    • Search Google Scholar
    • Export Citation
  • 109.

    KauffNDDomchekSMFriebelTM. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol2008;26:13311337.

    • Search Google Scholar
    • Export Citation
  • 110.

    KurianAWSigalBMPlevritisSK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol2010;28:222231.

    • Search Google Scholar
    • Export Citation
  • 111.

    DomchekSMFriebelTMSingerCF. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA2010;304:967975.

    • Search Google Scholar
    • Export Citation
  • 112.

    FinchAPLubinskiJMollerP. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol2014;32:15471553.

    • Search Google Scholar
    • Export Citation
  • 113.

    MarchettiCDe FeliceFPalaiaI. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health2014;14:150.

    • Search Google Scholar
    • Export Citation
  • 114.

    PowellCBKenleyEChenLM. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol2005;23:127132.

    • Search Google Scholar
    • Export Citation
  • 115.

    Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet1987;2:171175.

    • Search Google Scholar
    • Export Citation
  • 116.

    Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. Br J Cancer1988;57:604607.

    • Search Google Scholar
    • Export Citation
  • 117.

    FisherBCostantinoJRedmondC. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med1989;320:479484.

    • Search Google Scholar
    • Export Citation
  • 118.

    RutqvistLECedermarkBGlasU. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst1991;83:12991306.

    • Search Google Scholar
    • Export Citation
  • 119.

    Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 120.

    KingMCWieandSHaleK. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA2001;286:22512256.

    • Search Google Scholar
    • Export Citation
  • 121.

    CuzickJPowlesTVeronesiU. Overview of the main outcomes in breast-cancer prevention trials. Lancet2003;361:296300.

  • 122.

    PowlesTEelesRAshleyS. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet1998;352:98101.

    • Search Google Scholar
    • Export Citation
  • 123.

    PowlesTJAshleySTidyA. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst2007;99:283290.

    • Search Google Scholar
    • Export Citation
  • 124.

    VeronesiUMaisonneuvePSacchiniV. Tamoxifen for breast cancer among hysterectomised women. Lancet2002;359:11221124.

  • 125.

    VeronesiUMaisonneuvePCostaA. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet1998;352:9397.

    • Search Google Scholar
    • Export Citation
  • 126.

    VeronesiUMaisonneuvePRotmenszN. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst2007;99:727737.

    • Search Google Scholar
    • Export Citation
  • 127.

    VeronesiUMaisonneuvePRotmenszN. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst2003;95:160165.

    • Search Google Scholar
    • Export Citation
  • 128.

    BeversTB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother2001;55:559564.

  • 129.

    CuzickJForbesJEdwardsR. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet2002;360:817824.

    • Search Google Scholar
    • Export Citation
  • 130.

    CuzickJForbesJFSestakI. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst2007;99:272282.

    • Search Google Scholar
    • Export Citation
  • 131.

    CuzickJSestakICawthornS. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol2015;16:6775.

    • Search Google Scholar
    • Export Citation
  • 132.

    EttingerBBlackDMMitlakBH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA1999;282:637645.

    • Search Google Scholar
    • Export Citation
  • 133.

    CummingsSREckertSKruegerKA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:21892197.

    • Search Google Scholar
    • Export Citation
  • 134.

    MartinoSCauleyJABarrett-ConnorE. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004;96:17511761.

    • Search Google Scholar
    • Export Citation
  • 135.

    Barrett-ConnorEMoscaLCollinsP. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006;355:125137.

    • Search Google Scholar
    • Export Citation
  • 136.

    GradyDCauleyJAGeigerMJ. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst2008;100:854861.

    • Search Google Scholar
    • Export Citation
  • 137.

    LandSRWickerhamDLCostantinoJP. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:27422751.

    • Search Google Scholar
    • Export Citation
  • 138.

    BaumMBudzarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 139.

    BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer2003;98:18021810.

    • Search Google Scholar
    • Export Citation
  • 140.

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 141.

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 142.

    ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:27472757.

    • Search Google Scholar
    • Export Citation
  • 143.

    DecensiAGandiniSSerranoD. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol2007;25:42014209.

    • Search Google Scholar
    • Export Citation
  • 144.

    SiderasKIngleJNAmesMM. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol2010;28:27682776.

  • 145.

    HigginsMJStearnsV. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep2010;12:715.

  • 146.

    LashTLRosenbergCL. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol2010;28:12731275.

    • Search Google Scholar
    • Export Citation
  • 147.

    BeversTB. Breast cancer risk reduction therapy: the low-hanging fruit. J Natl Compr Canc Netw2015;13:376378.

  • 148.

    CurtinJKavanaghJ. Corpus: mesenchymal tumors. In: HoskinsWPerezCYoungR eds. Principles and Practice of Gynecologic Oncology. 3rd ed.Philadelphia, PA: J.B. Lippincott; 2000:961979.

    • Search Google Scholar
    • Export Citation
  • 149.

    BergmanLBeelenMLGalleeMP. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet2000;356:881887.

    • Search Google Scholar
    • Export Citation
  • 150.

    CurtisREFreedmanDMShermanMEFraumeniJFJr.Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst2004;96:7074.

    • Search Google Scholar
    • Export Citation
  • 151.

    WickerhamDLFisherBWolmarkN. Association of tamoxifen and uterine sarcoma. J Clin Oncol2002;20:27582760.

  • 152.

    BouchardyCVerkooijenHMFiorettaG. Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen. J Clin Oncol2002;20:4403.

    • Search Google Scholar
    • Export Citation
  • 153.

    RieckGCFreitesONWilliamsS. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol2005;25:3941.

    • Search Google Scholar
    • Export Citation
  • 154.

    WysowskiDKHonigSFBeitzJ. Uterine sarcoma associated with tamoxifen use. N Engl J Med2002;346:18321833.

  • 155.

    ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol2006;107:14751478.

  • 156.

    BarakatRRGilewskiTAAlmadronesL. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol2000;18:34593463.

    • Search Google Scholar
    • Export Citation
  • 157.

    FungMFReidAFaughtW. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol2003;91:154159.

    • Search Google Scholar
    • Export Citation
  • 158.

    GerberBKrauseAMullerH. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol2000;18:34643470.

    • Search Google Scholar
    • Export Citation
  • 159.

    GorinMBCostantinoJPKulacogluDN. Is tamoxifen a risk factor for retinal vaso-occlusive disease?Retina2005;25:523526.

  • 160.

    NayfieldSGGorinMB. Tamoxifen-associated eye disease. A review. J Clin Oncol1996;14:10181026.

  • 161.

    GradyDEttingerBMoscarelliE. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol2004;104:837844.

    • Search Google Scholar
    • Export Citation
  • 162.

    PowlesTJHickishTKanisJA. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol1996;14:7884.

    • Search Google Scholar
    • Export Citation
  • 163.

    SverrisdottirAFornanderTJacobssonH. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol2004;22:36943699.

    • Search Google Scholar
    • Export Citation
  • 164.

    VehmanenLElomaaIBlomqvistCSaartoT. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol2006;24:675680.

    • Search Google Scholar
    • Export Citation
  • 165.

    DecensiAMaisonneuvePRotmenszN. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation2005;111:650656.

    • Search Google Scholar
    • Export Citation
  • 166.

    BraithwaiteRSChlebowskiRTLauJ. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med2003;18:937947.

    • Search Google Scholar
    • Export Citation
  • 167.

    BushnellCDGoldsteinLB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology2004;63:12301233.

    • Search Google Scholar
    • Export Citation
  • 168.

    AbramsonNCostantinoJPGarberJE. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst2006;98:904910.

    • Search Google Scholar
    • Export Citation
  • 169.

    GuttusoTJr.KurlanRMcDermottMPKieburtzK. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol2003;101:337345.

    • Search Google Scholar
    • Export Citation
  • 170.

    GuttusoTJJr.Gabapentin's effects on hot flashes and hypothermia. Neurology2000;54:21612163.

  • 171.

    LoprinziLBartonDLSloanJA. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc2002;77:11591163.

  • 172.

    PandyaKJMorrowGRRoscoeJA. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet2005;366:818824.

    • Search Google Scholar
    • Export Citation
  • 173.

    LoprinziCLKuglerJWSloanJA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet2000;356:20592063.

    • Search Google Scholar
    • Export Citation
  • 174.

    StearnsVBeebeKLIyengarMDubeE. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA2003;289:28272834.

    • Search Google Scholar
    • Export Citation
  • 175.

    StearnsVSlackRGreepN. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol2005;23:69196930.

    • Search Google Scholar
    • Export Citation
  • 176.

    JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:3039.

    • Search Google Scholar
    • Export Citation
  • 177.

    MortimerJEFlattSWParkerBA. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat2008;108:421426.

  • 178.

    OsborneCRDuncanASedlacekS. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat2009;116:521527.

    • Search Google Scholar
    • Export Citation
  • 179.

    NelsonHDVescoKKHaneyE. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA2006;295:20572071.

    • Search Google Scholar
    • Export Citation
  • 180.

    GoldbergRMLoprinziCLO'FallonJR. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol1994;12:155158.

  • 181.

    LauferLRErlikYMeldrumDRJuddHL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol1982;60:583586.

  • 182.

    NagamaniMKelverMESmithER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol1987;156:561565.

    • Search Google Scholar
    • Export Citation
  • 183.

    BartonDLLoprinziCLQuellaSK. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol1998;16:495500.

    • Search Google Scholar
    • Export Citation
  • 184.

    PockajBAGallagherJGLoprinziCL. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol2006;24:28362841.

    • Search Google Scholar
    • Export Citation
  • 185.

    CarpenterJS. Hot flashes and their management in breast cancer. Semin Oncol Nurs2000;16:214225.

  • 186.

    FallowfieldLJBlissJMPorterLS. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol2006;24:910917.

    • Search Google Scholar
    • Export Citation
  • 187.

    MahoneyMC. Breast cancer risk reduction and counseling: lifestyle, chemoprevention, and surgery. J Natl Compr Canc Netw2007;5:702710.

    • Search Google Scholar
    • Export Citation
  • 188.

    VisvanathanKChlebowskiRTHurleyP. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol2009;27:32353258.

    • Search Google Scholar
    • Export Citation
  • 189.

    DaviesCPanHGodwinJ. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet2013;381:805816.

    • Search Google Scholar
    • Export Citation
  • 190.

    GrayRGReaDHandleyK. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer [abstract]. J Clin Oncol2013;31(Suppl):Abstract 5.

    • Search Google Scholar
    • Export Citation
  • 191.

    BursteinHJTeminSAndersonH. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update. J Clin Oncol2014;32:22552269.

    • Search Google Scholar
    • Export Citation
  • 192.

    BresserPJCVan GoolARSeynaeveC. Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?Ann Oncol2007;18:16411645.

    • Search Google Scholar
    • Export Citation
  • 193.

    PatenaudeAFOrozcoSLiX. Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psychooncology2008;17:831843.

    • Search Google Scholar
    • Export Citation
  • 194.

    van DijkSvan RoosmalenMSOttenWStalmeierPF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol2008;26:23582363.

    • Search Google Scholar
    • Export Citation
  • 195.

    GiulianoAEBoolbolSDegnimA. Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol2007;14:24252427.

    • Search Google Scholar
    • Export Citation
  • 196.

    MorrowMMehraraB. Prophylactic mastectomy and the timing of breast reconstruction. Br J Surg2009;96:12.

  • 197.

    RebbeckTRFriebelTWagnerT. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2005;23:78047810.

    • Search Google Scholar
    • Export Citation
  • 198.

    ChlebowskiRTPrenticeRL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst2008;100:13411343.

    • Search Google Scholar
    • Export Citation
  • 199.

    GarberJEHartmanAR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?J Clin Oncol2004;22:978980.

  • 200.

    GrannVRJacobsonJSThomasonD. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol2002;20:25202529.

    • Search Google Scholar
    • Export Citation
  • 201.

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA2002;288:321333.

    • Search Google Scholar
    • Export Citation
  • 202.

    AndersonGLLimacherMAssafAR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291:17011712.

    • Search Google Scholar
    • Export Citation
  • 203.

    McTiernanAMartinCFPeckJD. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst2005;97:13661376.

    • Search Google Scholar
    • Export Citation
  • 204.

    ChlebowskiRTAndersonGLGassM. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA2010;304:16841692.

    • Search Google Scholar
    • Export Citation
  • 205.

    ChlebowskiRTKullerLHPrenticeRL. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med2009;360:573587.

    • Search Google Scholar
    • Export Citation
  • 206.

    LaCroixAZChlebowskiRTMansonJE. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA2011;305:13051314.

    • Search Google Scholar
    • Export Citation
  • 207.

    StefanickMLAndersonGLMargolisKL. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA2006;295:16471657.

    • Search Google Scholar
    • Export Citation
  • 208.

    RohanTENegassaAChlebowskiRT. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst2008;100:563571.

    • Search Google Scholar
    • Export Citation
  • 209.

    McTiernanAChlebowskiRTMartinC. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol2009;27:61356143.

    • Search Google Scholar
    • Export Citation
  • 210.

    RosenbergLPalmerJRWiseLAAdams-CampbellLL. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med2006;166:760765.

    • Search Google Scholar
    • Export Citation
  • 211.

    BeralV. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet2003;362:419427.

  • 212.

    ChenWYMansonJEHankinsonSE. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med2006;166:10271032.

  • 213.

    ChlebowskiRT. Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol2009;36:566571.

  • 214.

    SantenRJAllredDC. The estrogen paradox. Nat Clin Pract Endocrinol Metab2007;3:496497.

  • 215.

    RossouwJEPrenticeRLMansonJE. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297:14651477.

    • Search Google Scholar
    • Export Citation
  • 216.

    FournierAMesrineSBoutron-RuaultMCClavel-ChapelonF. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?J Clin Oncol2009;27:51385143.

    • Search Google Scholar
    • Export Citation
  • 217.

    SuzukiRYeWRylander-RudqvistT. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst2005;97:16011608.

    • Search Google Scholar
    • Export Citation
  • 218.

    BagnardiVRotaMBotteriE. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol2013;24:301308.

  • 219.

    BernsteinLPatelAVUrsinG. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst2005;97:16711679.

    • Search Google Scholar
    • Export Citation
  • 220.

    HowardRALeitzmannMFLinetMSFreedmanDM. Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists cohort. Cancer Causes Control2009;20:323333.

    • Search Google Scholar
    • Export Citation
  • 221.

    LahmannPHFriedenreichCSchuitAJ. Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev2007;16:3642.

    • Search Google Scholar
    • Export Citation
  • 222.

    TehardBFriedenreichCMOppertJMClavel-ChapelonF. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev2006;15:5764.

    • Search Google Scholar
    • Export Citation
  • 223.

    FriedenreichCMWoolcottCGMcTiernanA. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol2010;28:14581466.

    • Search Google Scholar
    • Export Citation
  • 224.

    ChlebowskiRTChenZCauleyJA. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol2010;28:35823590.

    • Search Google Scholar
    • Export Citation
  • 225.

    PrenticeRLMansonJELangerRD. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol2009;170:1223.

    • Search Google Scholar
    • Export Citation
  • 226.

    MichelsKBWillettWC. The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. Breast Cancer Res Treat2009;114:16.

    • Search Google Scholar
    • Export Citation
  • 227.

    LinosEWillettWC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw2007;5:711718.

  • 228.

    TretliSGaardM. Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway. Cancer Causes Control1996;7:507512.

    • Search Google Scholar
    • Export Citation
  • 229.

    HuFBWillettWC. Optimal diets for prevention of coronary heart disease. JAMA2002;288:25692578.

  • 230.

    Bertone-JohnsonERChenWYHolickMF. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev2005;14:19911997.

    • Search Google Scholar
    • Export Citation
  • 231.

    BlackmoreKMLesoskyMBarnettH. Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol2008;168:915924.

    • Search Google Scholar
    • Export Citation
  • 232.

    KnightJALesoskyMBarnettH. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev2007;16:422429.

    • Search Google Scholar
    • Export Citation
  • 233.

    KotsopoulosJOlopadoOIGhadirianP. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res2005;7:R833843.

    • Search Google Scholar
    • Export Citation
  • 234.

    StuebeAMWillettWCXueFMichelsKB. Lactation and incidence of premenopausal breast cancer: a longitudinal study. Arch Intern Med2009;169:13641371.

    • Search Google Scholar
    • Export Citation
  • 235.

    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet2002;360:187195.

    • Search Google Scholar
    • Export Citation
  • 236.

    TryggvadottirLTuliniusHEyfjordJESigurvinssonT. Breastfeeding and reduced risk of breast cancer in an Icelandic cohort study. Am J Epidemiol2001;154:3742.

    • Search Google Scholar
    • Export Citation
  • 237.

    ZhengTHolfordTRMayneST. Lactation and breast cancer risk: a case-control study in Connecticut. Br J Cancer2001;84:14721476.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 145 145 19
PDF Downloads 32 32 4
EPUB Downloads 0 0 0